Buy Estradiol (Estrace, Progynova) tablets online

How and where to order Estrace, Progynova (Estradiol) 1 mg, 2 mg tablets online:

Shop:	DFH PHARMACY - 10% discount coupon DFH10
Sellers:	ESTRADIOL STORES
Prices:	from $0.68 per pill
Forms:	1 mg, 2 mg tablets
Quantity:	10-360 pills
Type:	Progynova brand, Estrace generic
Payment:	Visa, Mastercard, AmEx, Cryptocurrencies
Delivery:	Regular and express mail service
Shipping:	Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Estrace and Progynova (Estradiol) tablets is indicated in the:

Treatment of moderate to severe vasomotor symptoms associated with the menopause.

Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.

Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure.

Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease.

Treatment of prostate cancer and is similarly effective to other therapies such as androgen deprivation therapy with castration and antiandrogens.

Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).

Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate.

Birth control for hormonal contraception.

Lactation suppression: to suppress and cease lactation and breast engorgement in postpartum women.

Breast enhancement to increase the size of the breasts.

Oophorectomy: to restore estradiol levels in adult premenopausal women with hypogonadism, for instance those who have undergone oophorectomy.

Feminizing hormone therapy for transgender women: as part of feminizing hormone therapy for gender dysphoria, transgender women and some non-binary individuals.

Infertility: therapy of infertility in women when there is a need to develop sperm-friendly cervical mucus or an appropriate uterine lining.

Tall stature: to limit final height in adolescent girls with tall stature.

The adjunctive treatment of schizophrenia in women.

Sexual deviance. Estradiol has been used at high doses to suppress sex drive in men with sexual deviance such as paraphilias and in sex offenders.

Treatment of overactive bladder.

Contraindications:

Estradiol and other estrogens should not be used in individuals with any of the following conditions:

Undiagnosed abnormal genital bleeding.

Known, suspected or history of cancer of the breast except in appropriately selected patients being treated for metastatic disease.

Known or suspected estrogen-dependent neoplasia.

Active deep vein thrombosis, pulmonary embolism or history of these conditions.

Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction).

Liver dysfunction or disease.

Estrace should not be used in patients with known hypersensitivity to its ingredients.

Known or suspected pregnancy. There is no indication for Progynova and Estrace in pregnancy. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy.

Dosage forms and strengths:

Estrace (Estradiol) tablets 0.5 mg, 1 mg, 2 mg.

Progynova (Estradiol) tablets 1 mg, 2 mg.

Dosage and administration:

When estradiol pills are prescribed for a postmenopausal woman with a uterus, a progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be reevaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary. For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
Patients should be started at the lowest dose for the indication.

For menopausal hormone therapy of moderate to severe vasomotor symptoms, vulval and vaginal atrophy associated with the menopause, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible.
Attempts to discontinue or taper medication should be made at 3-month to 6-month intervals. The usual initial dosage range is 1 to 2 mg daily of estradiol adjusted as necessary to control presenting symptoms. The minimal effective dose for maintenance therapy should be determined by titration. Administration should be cyclic (e.g., 3 weeks on and 1 week off).

For treatment of female hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. Treatment is usually initiated with a dose of 1 to 2 mg daily of estradiol, adjusted as necessary to control presenting symptoms; the minimal effective dose for maintenance therapy should be determined by titration.

For treatment of breast cancer, for palliation only, in appropriately selected women and men with metastatic disease. Suggested dosage is 10 mg three times daily for a period of at least three months.

For treatment of advanced androgen-dependent carcinoma of the prostate, for palliation only.
Suggested dosage is 1 to 2 mg three times daily. The effectiveness of therapy can be judged by phosphatase determinations as well as by symptomatic improvement of the patient.

For prevention of osteoporosis.
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should be considered only for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate.

Warnings:

Cardiovascular disorders: coronary heart disease and stroke, venous thromboembolism.

Malignant neoplasms: endometrial cancer, breast cancer.

Dementia. 1.8% (and 0.9% women in the placebo group) received diagnoses of probable dementia.

Gallbladder disease. A 2- to 4-fold increase in the risk of gallbladder disease requiring surgery in postmenopausal women receiving estrogens has been reported.

Hypercalcemia. Estradiol administration may lead to severe hypercalcemia in patients with breast cancer and bone metastases. If hypercalcemia occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium level.

Visual abnormalities. Retinal vascular thrombosis has been reported in patients receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete loss of vision, or a sudden onset of proptosis, diplopia or migraine. If examination reveals papilledema or retinal vascular lesions, estrogens should be permanently discontinued.

Precautions:

Addition of a progestin when a woman has not had a hysterectomy.

Elevated blood pressure: blood pressure should be monitored at regular intervals with estrogen use.

Hypertriglyceridemia: in patients with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis and other complications.

Impaired liver function and past history of cholestatic jaundice: estrogens may be poorly metabolized in patients with impaired liver function.

Hypothyroidism: estrogen administration leads to increased thyroid-binding globulin (TBG) levels.

Fluid retention: because estrogens may cause some degree of fluid retention, patients with conditions that might be influenced by this factor, such as asthma, epilepsy, migraine, and cardiac or renal dysfunction, warrant careful observation when estrogens are prescribed.

Hypocalcemia: estradiol should be used with caution in individuals with severe hypocalcemia.

Ovarian cancer: the CE/MPA substudy of WHI reported that estrogen plus progestin increased the risk of ovarian cancer.

Exacerbation of endometriosis: endometriosis may be exacerbated with administration of estrogens.

Exacerbation of other conditions: estrogens may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine or porphyria, systemic lupus erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions.

Overdosage:

Serious ill effects have not been reported following acute ingestion of large doses of estrogen-containing oral contraceptives by young children. Overdosage of estradiol may cause nausea and vomiting, and withdrawal bleeding may occur in females.

Side effects, adverse reactions:

Most common adverse reactions of estradiol were: headache, breast pain, irregular vaginal bleeding or spotting, stomach/abdominal cramps, bloating, nausea, vomiting, hair loss.

To report suspected side effects of Estrace and Progynova (Estradiol) tablets contact Bristol-Myers Squibb and Bayer pharmaceutical companies or your local FDA.

Drug interactions:

In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4 such as St. John's Wort preparations (Hypericum perforatum), phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects.

Usage in specific populations:

Pregnancy

Pregnancy Category X. Progynova and Estrace (Estradiol) tablets should not be used during pregnancy.

Lactation

Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of the milk. Detectable amounts of estrogens have been identified in the milk of mothers receiving this drug. Caution should be exercised when this medication is administered to a nursing woman.

Pediatric use

Safety and effectiveness of estradiol pills in pediatric patients have not been established.

Geriatric use

The safety and efficacy of Estrace and Progynova tablets in geriatric patients has not been established. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greatest frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

Where to buy estradiol online:

To purchase Progynova, Estrace (Estradiol) 1 mg, 2 mg tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.

Here is a list of popular medications containing estradiol as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

Trade name of the drug	Pharmaceutical forms and doses	Companies
Climara	Film, Extended Release; Transdermal; Estradiol 0.025 mg, 0.0375 mg, 0.05 mg, 0.06 mg, 0.075 mg, 0.1 mg / 24 h	Bayer 3M Berlex Laboratories Perrigo
Depo-Estradiol	Injectable; Injection; Estradiol Cypionate 1 mg, 3 mg, 5 mg / ml	Pfizer
Estrace	Cream; Topical; Vaginal; Estradiol 0.01% Tablets; Oral; Estradiol 0.5 mg, 1 mg, 2 mg	AbbVie Acerus Pharmaceuticals Allergan Bristol-Myers Squibb Shire Warner Chilcott
Femring	Insert, Extended Release; Vaginal; Estradiol Acetate 0.05 mg, 0.1 mg / 24 h	Galen Warner Chilcott
Oestrogel	Gel; Topical; Estradiol 0.06%	Besins C.T.S. Chemical Industries Chemech Laboratories Enila Laboratorio Faran Laboratories FIC Medical IDS Group Invida Pliva Sanofi Tedis Vifor Pharma
Progynova	Tablets; Oral; Estradiol Valerate 1 mg, 2 mg	Bayer German Remedies Perrigo Schering-Plough Zydus Cadila

Medical Disclaimer:
All of the information contained in the menopause A to Z web site and any associated electronic publications, to include electronic books ("e-Books"), emails, newsletters and links are provided for educational and entertainment purposes ONLY. Neither the FDA, nor any other medical or government authority has evaluated the information. Nor does the information presented always represent the consensus of most physicians. The information is not intended to diagnose, treat, cure, or prevent any disease, nor should it be used as a therapeutic modality or as a substitute for your own physician's advice. Click Here to Read Full Medical Disclaimer

Medical Disclaimer | Estradiol | Terms of Service | Privacy Notice | Sitemap